OSS, NETHERLANDS – December 11th, 2019 – APO-T B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of dr Michael Saunders and dr Torsten Dreier.
Prof. Pierre van der Bruggen joins APO-T Scientific Advisory Board. Prof. van der Bruggen has identified the first human MAGE gen in 1991, coding for a tumor antigen recognized by cytolytic T lymphocytes.
Dr Allard Kaptein joins APO-T Scientific Advisory Board. Dr Kaptein has over 20 years experience in pharmaceutical industry where he held several project and line management positions.
APO-T appoints dr Marta Kijanka as acting CEO, who previously held VP of RD position at APO-T.
APO-T has been selected to give an IDEA Pitch at the upcoming Innovation for Health on 1st February 2018 in WTC Rotterdam.
